NEXGEL Announces Financing of $1.797 Million Relating to an Acquisition Targeted to Close in the First Quarter of 2026, Subject to the Completion of Due Diligence
MWN-AI** Summary
NEXGEL, Inc. (NASDAQ: NXGL), a provider of innovative healthcare and consumer products, announced a financing agreement totaling $1.797 million intended for a potential acquisition expected to close in the first quarter of 2026, pending due diligence completion. The funds will be returned to the investor if the transaction does not proceed. Adam Levy, CEO of NEXGEL, expressed confidence in the company's growth trajectory, citing a successful history of acquisitions and a commitment to ongoing strategic expansion.
The planned acquisition is part of NEXGEL's strategy to enhance its asset portfolio, supported by an upfront investment, with the possibility of an additional $14.869 million investment subject to further due diligence and other conditions. The company plans to keep its shareholders informed regarding the acquisition progress throughout the first quarter of 2026.
Palladium Capital Group, LLC plays a crucial role as the placement agent for this financing deal. NEXGEL has established itself as a leader in developing high-water-content hydrogel products for both healthcare and consumer applications, with notable brands such as SilverSeal®, Hexagels®, and Turfguard®. The company, based in Langhorne, Pennsylvania, has over 20 years of experience in creating electron-beam, cross-linked hydrogels and maintains strategic partnerships in the consumer healthcare sector.
Importantly, the announcement includes forward-looking statements regarding NEXGEL's future performance, which involve inherent risks and uncertainties, emphasizing that actual results may differ significantly from projections. Stakeholders are encouraged to refer to the company's Annual Report for more detailed risk factors impacting these statements.
MWN-AI** Analysis
NEXGEL, Inc. (NASDAQ: NXGL) recently announced a financing deal totaling $1.797 million as part of a potential acquisition set to close in Q1 2026. This development demonstrates the company's ongoing strategic growth efforts in the healthcare and consumer product sectors. Investors should approach this news with cautious optimism, weighing the implications of both the financing and the acquisition potential.
The financing represents an initial commitment that could signal investor confidence in NEXGEL's growth strategy. However, key to this deal is the completion of due diligence, indicating that uncertainties remain. Investors need to monitor the situation closely, especially given that the funds will be returned should the acquisition fail to materialize.
Historically, NEXGEL has shown a capacity for successfully integrating acquisitions, which may enhance its market position and product offerings. The company's focus on high-water-content hydrogel products aligns well with rising consumer demand in healthcare and beauty, suggesting that an acquisition with successful integration could be accretive to earnings.
The potential for an additional investment of $14.869 million contingent upon due diligence completion further highlights ambitious growth plans. However, investors should also consider risks, including market volatility, the effectiveness of the due diligence process, and acquisition integration challenges.
In light of these developments, we advise investors to keep an eye on the progress of the due diligence phase and any related announcements that may impact share price. If the acquisition is completed, NEXGEL could see significant value creation, making it a potentially strong investment opportunity. Conversely, should the deal fall through, investors may want to reassess their positions based on the company's performance and market conditions. Ultimately, due diligence on both the deal and the company's operational health will be crucial for making informed investment decisions.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
LANGHORNE, Pa., Feb. 10, 2026 (GLOBE NEWSWIRE) -- NEXGEL, Inc. (“NEXGEL” or the “Company”) (NASDAQ: “NXGL”), a leading provider of healthcare, beauty, and over-the-counter (OTC) products including ultra-gentle, high-water-content hydrogel products for healthcare and consumer applications, today announced the financing of $1.797 million relating to a potential acquisition targeted for the first quarter of 2026. The potential acquisition is subject to the completion of due diligence by both NEXGEL and the investor. The funds will be returned to the investor should the transaction not be consummated.
“After successfully closing and integrating several acquisitions over the last several years, we have continued to evaluate other potential accretive transactions,” said Adam Levy, CEO of NEXGEL. “We have identified assets to acquire with an up-front commitment from an investor in the amount of $1.797 million and a potential additional investment of $14.869 million relating to the acquisition, pending the completion of full due diligence by both parties and subject to other conditions. We expect to provide shareholders with further information on the acquisition during the first quarter of 2026.”
Palladium Capital Group, LLC acted as the placement agent on the transaction.
The financing transaction is more fully described in the Current Report on Form 8-K filed with the Securities and Exchange Commission on February 10, 2026.
About NEXGEL, Inc.
NEXGEL is a leading provider of healthcare, beauty, and over-the-counter (OTC) products including ultra-gentle, high-water-content hydrogel products for healthcare and consumer applications. Based in Langhorne, Pa., the Company has developed and manufactured electron-beam, cross-linked hydrogels for over two decades. NEXGEL brands include SilverSeal®, Hexagels®, Turfguard®, Kenkoderm® and Silly George®. Additionally, NEXGEL has strategic contract manufacturing relationships with leading consumer healthcare companies.
Forward-Looking Statement
This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) (which Sections were adopted as part of the Private Securities Litigation Reform Act of 1995). Statements preceded by, followed by or that otherwise include the words “believe,” “anticipate,” “estimate,” “expect,” “intend,” “plan,” “potential,” “project,” “prospects,” “outlook,” and similar words or expressions, or future or conditional verbs, such as “will,” “should,” “lends,” “would,” “may,” and “could,” are generally forward-looking in nature and not historical facts, including, without limitation, our ability to consummate the potential acquisition and the related additional investment. These forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the Company's actual results, performance, or achievements to be materially different from any anticipated results, performance, or achievements for many reasons. The Company disclaims any intention to, and undertakes no obligation to, revise any forward-looking statements, whether as a result of new information, a future event, or otherwise. For additional risks and uncertainties that could impact the Company's forward-looking statements, please see the Company's Annual Report on Form 10-K for the year ended December 31, 2024, including but not limited to the discussion under “Risk Factors” therein, which the Company filed with the SEC and which may be viewed at http://www.sec.gov/.
Investor Contacts:
Valter Pinto, Managing Director
KCSA Strategic Communications
212.896.1254
Nexgel@KCSA.com
FAQ**
How might the potential acquisition and related financing impact the performance and share price of NEXGEL, Inc. Warrant NXGLW in the upcoming quarters?
What specific criteria will NEXGEL use during its due diligence process to evaluate the target acquisition and how could this affect NEXGEL, Inc. Warrant NXGLW?
Can you provide insights into how the additional investment of $14.869 million will be allocated and its potential effects on the valuation of NEXGEL, Inc. Warrant NXGLW?
Given NEXGEL's recent successes with acquisitions, what synergies do you anticipate from this transaction that may influence NEXGEL, Inc. Warrant NXGLW's future growth trajectory?
**MWN-AI FAQ is based on asking OpenAI questions about NexGel Inc (NASDAQ: NXGL).
NASDAQ: NXGL
NXGL Trading
2.64% G/L:
$1.1701 Last:
19,819 Volume:
$1.15 Open:
